Compare WHG & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WHG | ENTX |
|---|---|---|
| Founded | 1983 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.9M | 142.0M |
| IPO Year | 2002 | 2018 |
| Metric | WHG | ENTX |
|---|---|---|
| Price | $18.26 | $1.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 12.6K | ★ 77.7K |
| Earning Date | 10-30-2025 | 11-14-2025 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | ★ 154.57 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $96,243,000.00 | $124,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.09 | ★ N/A |
| Revenue Growth | 4.20 | ★ 25.25 |
| 52 Week Low | $13.49 | $1.50 |
| 52 Week High | $18.97 | $3.22 |
| Indicator | WHG | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 71.62 | 32.11 |
| Support Level | $16.12 | $2.07 |
| Resistance Level | $18.47 | $2.22 |
| Average True Range (ATR) | 0.53 | 0.15 |
| MACD | 0.22 | -0.02 |
| Stochastic Oscillator | 96.64 | 0.72 |
Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.